Serum palivizumab level is associated with decreased severity of respiratory syncytial virus disease in high-risk infants

Human Vaccines and Immunotherapeutics

Volumn 10, Issue 10, 2014, Pages 2789-2794

  Forbes, Michael L ^a   Kumar, Veena R ^b   Yogev, Ram ^c   Wu, Xionghua ^d   Robbie, Gabriel J ^d   Ambrose, Christopher S ^b  

^a AKRON CHILDREN'S HOSPITAL   (United States)

^b ASTRAZENECA   (United Kingdom)

^c CHILDREN'S MEMORIAL HOSPITAL   (United States)

^d MEDIMMUNE   (United States)

Author keywords

IMpact RSV study; Palivizumab; Pediatric intensive care unit; Respiratory syncytial virus; RSV related hospitalization; Serum palivizumab level; Severe RSV disease

Indexed keywords

PALIVIZUMAB; ANTIVIRUS AGENT; MONOCLONAL ANTIBODY;

ARTICLE; ARTIFICIAL VENTILATION; CHILD; CLINICAL ARTICLE; CONCENTRATION RESPONSE; DISEASE ASSOCIATION; DISEASE SEVERITY; DRUG BLOOD LEVEL; FEMALE; GESTATIONAL AGE; HIGH RISK INFANT; HOSPITAL ADMISSION; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; LENGTH OF STAY; LUNG DYSPLASIA; MALE; MULTICENTER STUDY (TOPIC); OXYGEN THERAPY; POST HOC ANALYSIS; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESPIRATORY SYNCYTIAL VIRUS INFECTION; SENSITIVITY AND SPECIFICITY; TREATMENT DURATION; BLOOD; BRONCHOPULMONARY DYSPLASIA; CONTROLLED STUDY; DISEASE COURSE; HUMAN RESPIRATORY SYNCYTIAL VIRUS; IMMUNOLOGY; INFANT; PREMATURITY; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RETROSPECTIVE STUDY; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIVIRAL AGENTS; BRONCHOPULMONARY DYSPLASIA; DISEASE PROGRESSION; FEMALE; HOSPITALIZATION; HUMANS; INFANT; INFANT, PREMATURE; INTENSIVE CARE UNITS, PEDIATRIC; MALE; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RETROSPECTIVE STUDIES; RISK; RISK FACTORS;

EID: 84921362608     PISSN: 21645515     EISSN: 2164554X     Source Type: Journal    
DOI: 10.4161/hv.29635     Document Type: Article

References (26)

1. Brandt CD, Kim HW, Arrobio JO, Jeffries BC, Wood SC, Chanock RM, Parrott RH. Epidemiology of respiratory syncytial virus infection in Washington, D.C. 3. Composite analysis of eleven consecutive yearly epidemics. Am J Epidemiol 1973; 98:355-64; PMID: 4355632
2. Glezen WP, Loda FA, Clyde WA Jr., Senior RJ, Sheaffer CI, Conley WG, Denny FW. Epidemiologic patterns of acute lower respiratory disease of children in a pediatric group practice. J Pediatr 1971; 78:397-406; PMID:5101436; http://dx.doi.org/10.1016/S0022-3476(71)80218-4
3. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986; 140:543-6; PMID: 3706232
4. Shay DK, Holman RC, Newman RD, Liu LL, Stout JW, Anderson LJ. Bronchiolitis-associated hospitalizations among US children, 1980-1996. JAMA 1999; 282:1440-6; PMID:10535434; http://dx.doi.org/10.1001/jama.282.15.1440
5. Stockman LJ, Curns AT, Anderson LJ, Fischer-Langley G. Respiratory syncytial virus-associated hospitalizations among infants and young children in the United States, 1997-2006. Pediatr Infect Dis J 2012; 31:5-9; PMID:21817948; http://dx.doi.org/10.1097/INF.0b013e31822e68e6
6. Thompson WW, Shay DK, Weintraub E, Brammer L, Cox N, Anderson LJ, Fukuda K. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA 2003; 289:179-86; PMID: 12517228; http://dx.doi.org/10.1001/jama.289.2.179
7. Shay DK, Holman RC, Roosevelt GE, Clarke MJ, Anderson LJ. Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997. J Infect Dis 2001; 183:16-22; PMID:11076709; http://dx.doi.org/10.1086/317655
8. The IMpact-RSV Study Group. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998; 102:531-7; http://dx.doi.org/10.1542/peds.102.3.531
9. Feltes TF, Cabalka AK, Meissner HC, Piazza FM, Carlin DA, Top FH Jr., Connor EM, Sondheimer HM; Cardiac Synagis Study Group. Palivizumab prophylaxis reduces hospitalization due to respiratory syncytial virus in young children with hemodynamically significant congenital heart disease. J Pediatr 2003; 143:532-40; PMID:14571236; http://dx.doi.org/10.1067/S0022-3476(03)00454-2
10. Lamprecht CL, Krause HE, Mufson MA. Role of maternal antibody in pneumonia and bronchiolitis due to respiratory syncytial virus. J Infect Dis 1976; 134:211-7; PMID:977992; http://dx.doi.org/10.1093/infdis/134.3.211
11. Ogilvie MM, Vathenen AS, Radford M, Codd J, Key S. Maternal antibody and respiratory syncytial virus infection in infancy. J Med Virol 1981; 7:263-71; PMID: 7038043; http://dx.doi.org/10.1002/jmv.1890070403
12. Kasel JA, Walsh EE, Frank AL, Baxter BD, Taber LH, Glezen WP. Relation of serum antibody to glycoproteins of respiratory syncytial virus with immunity to infection in children. Viral Immunol 1987-1988; 1:199-205; PMID:3509676; http://dx.doi.org/10.1089/vim.1987.1.199
13. Groothuis JR, Simoes EA, Levin MJ, Hall CB, Long CE, Rodriguez WJ, Arrobio J, Meissner HC, Fulton DR, Welliver RC, et al.; The Respiratory Syncytial Virus Immune Globulin Study Group. Prophylactic administration of respiratory syncytial virus immune globulin to high-risk infants and young children. N Engl J Med 1993; 329:1524-30; PMID:8413475; http://dx.doi.org/10.1056/NEJM199311183292102
14. The PREVENT Study Group. Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globulin prophylaxis. Pediatrics 1997; 99:93-9; PMID:8989345; http://dx.doi.org/10.1542/peds.99.1.93
15. Palivizumab. Full Prescribing Information, MedImmune, Gaithersburg, MD, 2014.
16. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176:1215-24; PMID:9359721; http://dx.doi.org/10.1086/514115
17. Subramanian KN, Weisman LE, Rhodes T, Ariagno R, Sánchez PJ, Steichen J, Givner LB, Jennings TL, Top FH Jr., Carlin D, et al. Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:110-5; PMID: 9493805; http://dx.doi.org/10.1097/00006454-199802000-00006
18. Sáez-Llorens X, Castaño E, Null D, Steichen J, Sánchez PJ, Ramilo O, Top FH Jr., Connor E. Safety and pharmacokinetics of an intramuscular humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. The MEDI-493 Study Group. Pediatr Infect Dis J 1998; 17:787-91; PMID:9779762; http://dx.doi.org/10.1097/00006454-199809000-00007
19. MedCalc Statistical Software. Ostend, Belgium: Med- Calc Software bvba; 2014
20. Committee on Infectious Diseases. From the American Academy of Pediatrics: Policy statements-Modified recommendations for use of palivizumab for prevention of respiratory syncytial virus infections. Pediatrics 2009; 124:1694-701; PMID:19736258; http://dx.doi.org/10.1542/peds.2009-2345
21. Robinson J. Preventing respiratory syncytial virus infections. Paediatr Child Health 2011; 16:487-90; PMID:23024588
22. Wu H, Pfarr DS, Johnson S, Brewah YA, Woods RM, Patel NK, White WI, Young JF, Kiener PA. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J Mol Biol 2007; 368:652-65; PMID:17362988; http://dx.doi.org/10.1016/j.jmb.2007.02.024
23. Johnson S, Griego SD, Pfarr DS, Doyle ML, Woods R, Carlin D, Prince GA, Koenig S, Young JF, Dillon SB. A direct comparison of the activities of two humanized respiratory syncytial virus monoclonal antibodies: MEDI-493 and RSHZl9. J Infect Dis 1999; 180:35-40; PMID:10353858; http://dx.doi.org/10.1086/314846
24. La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther 2013; 26:666-71; PMID:23523663; http://dx.doi.org/10.1016/j.pupt.2013.03.007
25. Robbie GJ, Zhao L, Mondick J, Losonsky G, Roskos LK. Population pharmacokinetics of palivizumab, a humanized anti-respiratory syncytial virus monoclonal antibody, in adults and children. Antimicrob Agents Chemother 2012; 56:4927-36; PMID:22802243; http://dx.doi.org/10.1128/AAC.06446-11
26. Frogel MP, Stewart DL, Hoopes M, Fernandes AW, Mahadevia PJ. A systematic review of compliance with palivizumab administration for RSV immunoprophylaxis. J Manag Care Pharm 2010; 16:46-58; PMID:20131495